WO2004009032A3 - Method and composition for treating and preventing hepatitis b infection and symptoms thereof - Google Patents
Method and composition for treating and preventing hepatitis b infection and symptoms thereof Download PDFInfo
- Publication number
- WO2004009032A3 WO2004009032A3 PCT/US2003/022961 US0322961W WO2004009032A3 WO 2004009032 A3 WO2004009032 A3 WO 2004009032A3 US 0322961 W US0322961 W US 0322961W WO 2004009032 A3 WO2004009032 A3 WO 2004009032A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- symptoms
- treating
- infection
- composition
- patient
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 title 1
- 230000034303 cell budding Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003254129A AU2003254129A1 (en) | 2002-07-19 | 2003-07-21 | Method and composition for treating and preventing hepatitis b infection and symptoms thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39705402P | 2002-07-19 | 2002-07-19 | |
US60/397,054 | 2002-07-19 | ||
US45302803P | 2003-03-07 | 2003-03-07 | |
US60/453,028 | 2003-03-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004009032A2 WO2004009032A2 (en) | 2004-01-29 |
WO2004009032A3 true WO2004009032A3 (en) | 2004-10-21 |
Family
ID=30772984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/022961 WO2004009032A2 (en) | 2002-07-19 | 2003-07-21 | Method and composition for treating and preventing hepatitis b infection and symptoms thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003254129A1 (en) |
WO (1) | WO2004009032A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2091971A4 (en) * | 2006-11-13 | 2010-05-05 | Functional Genetics Inc | Therapeutic targeting of escort proteins |
CN100586474C (en) * | 2006-12-28 | 2010-02-03 | 北京炎黄麒麟生物技术开发有限公司 | Medicine composition, kit and application thereof |
KR100949310B1 (en) * | 2007-11-21 | 2010-03-23 | 한국과학기술연구원 | Method for detection of the interaction HBV capsid and surface proteins using cellular imaging, and screening method of inhibitory agent of HBV proliferation using thereof |
US9963751B2 (en) | 2015-11-24 | 2018-05-08 | The Penn State Research Foundation | Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA |
CN107254000A (en) * | 2017-08-09 | 2017-10-17 | 芜湖英特菲尔生物制品产业研究院有限公司 | A kind of fusion protein being made up of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of restructuring sheep long-acting interferon γ |
-
2003
- 2003-07-21 WO PCT/US2003/022961 patent/WO2004009032A2/en not_active Application Discontinuation
- 2003-07-21 AU AU2003254129A patent/AU2003254129A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
PARENT L.J. ET AL: "Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins", JOURNAL OF VIROLOGY, vol. 69, no. 9, September 1995 (1995-09-01), pages 5455 - 5460, XP002979975 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004009032A2 (en) | 2004-01-29 |
AU2003254129A8 (en) | 2004-02-09 |
AU2003254129A1 (en) | 2004-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002248384A1 (en) | Serpin drugs for treatment of hiv infection and method of use thereof | |
WO2005084295A3 (en) | Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3 | |
WO2003089619A3 (en) | Placental derived stem cells and uses thereof | |
WO2005037214A3 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
WO2006124012A3 (en) | Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production | |
WO2007001406A3 (en) | Aryl-containing macrocyclic compounds | |
WO2005042703A3 (en) | Placental stem cells and uses thereof | |
TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
WO2005021707A3 (en) | Severe acute respiratory syndrome dna vaccine compositions and methods of use | |
WO2003087092A3 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
WO2005095403A3 (en) | Macrocyclic compounds as inhibitors of viral replication | |
HK1197656A1 (en) | Treatment of glycogen storage disease type ii ii | |
EP1444889A4 (en) | Transgenic animal | |
WO2001023421A3 (en) | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease | |
WO2002004421A3 (en) | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics | |
WO2005002526A3 (en) | Method and compositions for treatment of viral infections | |
WO2006041409A8 (en) | Medical solution, method for producing and use thereof | |
WO2003059262A3 (en) | Method and composition for treating and preventing hiv infection and aids | |
WO2004009032A3 (en) | Method and composition for treating and preventing hepatitis b infection and symptoms thereof | |
WO2005058934A3 (en) | Glycosylated steroid derivatives with anti-migratory activity | |
WO2004016738A3 (en) | Method and composition for treating and preventing hepatitis c infection | |
CA2482021A1 (en) | Removal of adenine during a process of pathogen reducing blood and blood components | |
WO2002060954A8 (en) | Materials and methods for treatment of hepatitis c | |
WO2004009028A3 (en) | Method and composition for treating and preventing influenza infection and symptoms thereof | |
WO2005040428A3 (en) | Detection of mutations in a gene associated with resistance to viral infection, oas1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |